Number of the records: 1  

Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction

  1. 1.
    0563164 - ÚOCHB 2023 RIV NL eng J - Journal Article
    Radilová, Kateřina - Zima, Václav - Král, Michal - Machara, Aleš - Majer, Pavel - Hodek, Jan - Weber, Jan - Brynda, Jiří - Strmeň, Timotej - Konvalinka, Jan - Kožíšek, Milan
    Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction.
    Antiviral Research. Roč. 208, December (2022), č. článku 105449. ISSN 0166-3542. E-ISSN 1872-9096
    R&D Projects: GA MŠMT(CZ) EF16_019/0000729; GA MŠMT(CZ) LX22NPO5103
    Institutional support: RVO:61388963
    Keywords : antiviral peptides * influenza A polymerase * protein-protein interaction * AlphaScreen * isothermal titration calorimetry
    OECD category: Biochemistry and molecular biology
    Impact factor: 7.6, year: 2022
    Method of publishing: Open access
    https://doi.org/10.1016/j.antiviral.2022.105449

    Influenza virus causes severe respiratory infection in humans. Current antivirotics target three key proteins in the viral life cycle: neuraminidase, the M2 channel and the endonuclease domain of RNA-dependent-RNA polymerase. Due to the development of novel pandemic strains, additional antiviral drugs targetting different viral proteins are still needed. The protein-protein interaction between polymerase subunits PA and PB1 is one such possible target. We recently identified a modified decapeptide derived from the N-terminus of the PB1 subunit with high affinity for the C-terminal part of the PA subunit. Here, we optimized its amino acid hotspots to maintain the inhibitory potency and greatly increase peptide solubility. This allowed thermodynamic characterization of peptide binding to PA. Solving the X-ray structure of the peptide-PA complex provided structural insights into the interaction. Additionally, we optimized intracellular delivery of the peptide using a bicyclic strategy that led to improved inhibition in cell-based assays.
    Permanent Link: https://hdl.handle.net/11104/0335206

     
    FileDownloadSizeCommentaryVersionAccess
    10.1016j.antiviral.2022.105449.pdf56.4 MBPublisher’s postprintopen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.